GEHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GE Healthcare Technologies (GEHC) is not a strong buy right now for a beginner investor with a long-term focus, but it is a reasonable hold and watchlist name. The stock has constructive momentum, supportive insider/congress buying, and positive analyst upside targets, but the recent analyst revisions show meaningful caution after a weaker quarter and lowered guidance. Since the user is impatient and does not want to wait for the best entry, I would still avoid calling this a buy today because the near-term setup is mixed rather than clearly bullish.
GEHC is trading near a short-term pivot area around 63.47-65.90, with the current price at 65.435 sitting just below R1 at 65.904. MACD histogram is positive and expanding, which supports near-term upward momentum. RSI_6 at 61.884 is neutral-to-mildly bullish, not overbought. Moving averages are converging, suggesting the stock is trying to establish a trend but has not fully broken out yet. The nearby resistance zone is 65.904 to 67.407, while support is 63.47 and then 61.037. Overall, the chart is constructive but not decisive.
["RBC Capital initiated coverage with an Outperform rating and $80 target, citing attractive risk/reward and backlog-driven growth later in 2026.", "Insiders have been buying, with buying amount up 1425.73% over the last month.", "Congress members showed net positive activity with 1 purchase and 0 sales in the last 90 days.", "MACD is positive and expanding, indicating improving short-term trend momentum.", "A cash dividend was declared for Q2 2026, reinforcing shareholder return stability."]
["Several major firms cut price targets after quarterly results, signaling concern about near-term execution and margin pressure.", "JPMorgan and Citi are Neutral with $65 targets, implying limited immediate upside from current levels.", "Goldman Sachs downgraded the stock to Neutral from Buy after the Q1 report and cited macro exposure and rising input costs.", "Hedge funds are selling, with selling increasing 129.92% over the last quarter.", "The company recently missed earnings and lowered 2026 guidance, which remains a key overhang."]
The latest quarter appears to be Q1 2026 based on the analyst commentary. The company missed earnings and lowered 2026 EPS guidance to $4.80-$5.00 from $4.95-$5.15, below the $5.06 consensus referenced by Citi. Analysts noted stronger backlog and commercial execution, but these positives were offset by higher inflationary and input-cost pressures. The financial trend is mixed: long-term growth drivers remain in place, but near-term earnings momentum weakened in the latest quarter.
Analyst sentiment is mixed to mildly positive overall. Recent target cuts show the Street has become more cautious after Q1 results, with multiple firms moving to Neutral/Equal Weight or lowering targets to the mid-$60s. However, several firms still rate it Outperform/Overweight/Buy and keep targets in the $78-$88 range, while RBC's new $80 target and positive initiation improve the long-term view. Wall Street's bull case is strong backlog, R&D investment, product pipeline, and later-2026 growth acceleration. The bear case is margin pressure, macro exposure, China/tariff concerns, and the recent guidance reset. Net: pros still exist, but the Street is not uniformly bullish in the near term.
